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Abstract
Background: The main objective of this study was to evaluate the safety of second-line
pemetrexed in Stage IIIB or IV NSCLC.
Methods: Overall, 95 patients received pemetrexed 500 mg/m2 i.v. over Day 1 of a 21-day cycle.
Patients also received oral dexamethasone, oral folic acid and i.m. vitamin B12 supplementation to
reduce toxicity. NCI CTC 2.0 was used to rate toxicity. All the adverse events were graded in
terms of severity and relation to study treatment. Dose was reduced in case of toxicity and
treatment was delayed for up to 42 days from Day 1 of any cycle to allow recovering from study
drug-related toxicities. Tumor response was measured using the RECIST criteria.
Results: Patients received a median number of 4 cycles and 97.8% of the planned dose. Overall,
75 patients (78.9% of treated) reported at least one adverse event: 34 (35.8%) had grade 3 as worst
grade and only 5 (5.2%) had grade 4. Drug-related events occurred in 57.9% of patients.
Neutropenia (8.4%) and leukopenia (6.3 %) were the most common grade 3/4 hematological
toxicities. Grade 3 anemia and thrombocytopenia were reported in 3.2% and 2.1% of patients,
respectively. Diarrhea (6.3%), fatigue (3.2%) and dyspnea (3.2%) were the most common grade 3/
4 non-hematological toxicities. The most common drug-related toxicities (any grade) were pyrexia
(11.6%), vomiting, nausea, diarrhea and asthenia (9.5%) and fatigue (8.4%). Tumor Response Rate
(CR/PR) in treated patients was 9.2%. The survival at 4.5 months (median follow-up) was 79% and
the median PFS was 3.1 months. Twenty patients (21.1%) died mainly because of disease
progression.
Conclusion: Patients with locally advanced or metastatic NSCLC could benefit from second-line
pemetrexed, with a low incidence of hematological and non-hematological toxicities.
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Lung cancer is more often diagnosed and is by far the
most common cause of death from cancer in both genders
worldwide [1,2]. Almost 80% of lung cancers can be clas-
sified as Non Small Cell Lung Cancer (NSCLC), with 65%
to 75% of cases presenting as locally advanced (Stage III)
or metastatic disease (Stage IV) [3,4].
Significant improvements in median survival in advanced
NSCLC patients have been achieved with the use of plati-
num-based chemotherapy [5], particularly in patients
with good performance status, and with newer cytotoxic
agents, such as gemcitabine, paclitaxel, docetaxel or vinor-
elbine [6,7]. It is actually believed that the next significant
advance in the treatment of NSCLC might derive from the
use of targeted agents, as monotherapy or in combination
with standard chemotherapy regimens, without increas-
ing toxicity [6].
Pemetrexed is a new multi-target antifolate agent
approved for the treatment of malignant pleural mesothe-
lioma and NSCLC. Pemetrexed exerts its cytotoxic effect
through inhibition of Thymidylate Synthase, Dihydro-
folate Reductase and Glycinamide Ribonucleotide Formyl
Transferase [8], which are involved in DNA synthesis and
folate metabolism [9]. The multiple inhibitions of several
key folate-requiring enzymes may account both for the
antitumor activity and the potential cytotoxic effect of
pemetrexed. It has been found that the hematological and
non-hematological toxicities of pemetrexed can be
reduced through routine vitamin supplementation (folic
acid and vitamin B12), without loss of efficacy [10].
Several reports have documented the effects of peme-
trexed given as a single agent and in combination in first-
or second-line chemotherapy in advanced NSCLC [11]. In
phase II trials, pemetrexed has shown high efficacy and
favorable toxicity when given in combination with plati-
num agents, gemcitabine and vinorelbine [12,13]. A
recent phase III trial that compared pemetrexed with
docetaxel in previously treated NSCLC patients showed
equivalent efficacy in response rate and survival, and sig-
nificantly less toxicity in the pemetrexed group when
compared to docetaxel [14].
According to Italian legislation, which establishes a drug
dispensing as 'therapeutic use' prior to approval for use in
local market, this study was aimed at extending the clini-
cal experience with pemetrexed in pretreated patients with
locally advanced or metastatic NSCLC.
Methods
Patients
Adult patients of both genders with locally advanced or
metastatic NSCLC (Stage IIIB or IV at entry), previously
treated with no more than two chemotherapy regimens
for advanced disease, were eligible for the study. Prior
chemotherapy and/or radiotherapy (excluding peme-
trexed) were to be completed at least 2 weeks prior to
study enrollment and the patients should have recovered
from any acute toxic effect of previous therapy. Prior radi-
ation therapy allowed to < 25% of the bone marrow.
Moreover, eligible patients were required to have a ECOG
Performance Status 0 to 2, an estimated life expectation of
at least 8 weeks, and an adequate bone marrow reserve.
Patients with evidence of hepatic or renal insufficiency,
active infection, inability to take folic acid, vitamin B12
supplementation or corticosteroids, signs of malnourish-
ment or > 10% weight loss in the past 6 weeks, or others
serious concomitant disorders (including oncologic emer-
gencies) were excluded from the study. Pregnant or breast-
feeding females were also not allowed to taking part in the
study, as well as an adequate contraceptive method was to
be used for the whole study duration. Patients were to be
discontinued from the study in the case of evidence of
progressive disease or unacceptable toxicity despite dose
adjustment.
The participant patients gave their written informed con-
sent prior to enter in the study. The study protocol and the
informed consent form were reviewed and approved by
the Independent Ethics Committees of each participating
center prior to any study-related procedure was started.
Treatments
Pemetrexed 500 mg/m2 (Alimta®, Eli Lilly and Company,
Indianapolis, IN) was administered i.v. over approxi-
mately 10 minutes on Day 1 of a 21-day cycle. Dexameth-
asone 4 mg or equivalent corticosteroid was taken orally
twice daily on the day before, the day of, and the day after
each dose of pemetrexed. Folic acid supplementation 350
to 600 μg or equivalent was taken orally daily beginning
approximately 1 to 2 weeks prior to the first dose of peme-
trexed and continued until 3 weeks after study therapy dis-
continuation. Patients also received a 1000 μg vitamin
B12 i.m. injection approximately 1 to 2 weeks prior to the
first dose of pemetrexed, to be repeated approximately
every 9 weeks until 3 weeks after study therapy discontin-
uation.
Any patient who required a pemetrexed dose reduction
due to hematological or non-hematological toxicities was
treated further according to dose reductions. Any patient
requiring > 2 reductions due to toxicity was to be with-
drawn from study therapy. Treatment could have been
delayed for up to 42 days from Day 1 of any cycle to allow
recovering from study drug-related toxicities.
No other chemotherapy, immunotherapy, hormonal can-
cer therapy, radiation therapy, surgery for cancer, or anyPage 2 of 7
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study. Disease progression requiring alternative antitu-
mor treatment led to early discontinuation of study ther-
apy. If patient required radiotherapy treatment (both
palliative or not) during the study, pemetrexed was dis-
continued until 2 weeks after the completion of radiation
treatment.
The use of growth factors was not allowed by study proto-
col.
Outcome measures
The analysis of safety was the primary endpoint of the
study. The safety measures used in the study included
adverse events, physical examinations and clinical labora-
tory tests (hematology, blood chemistry and urinary creat-
inine clearance). All the adverse events were evaluated in
terms of severity and relation to study treatment, while
toxicities according to the National Cancer Institute Com-
mon Toxicity Criteria (NCI CTC) version 2.0 [15].
The evaluation of the best tumor response rate was per-
formed at the end of the treatment period and the
Response Evaluation Criteria in Solid Tumors (RECIST)
were recommended [16]. The progression free survival
(PFS) was the time from study entry to disease progression
or death, while the overall survival time was defined as the
time from study entry to death due to any cause. Investi-
gators followed-up the survival status of patients who had
discontinued study therapy.
Adverse events were considered those emerging during
treatment or present at baseline and worsening during the
study.
Statistics
The statistical analysis was performed using the SAS ver-
sion 8.2 (Cary, NC, US). The analyses were mainly
descriptive: summary statistics were given for patient char-
acteristics, treatment administration and all safety varia-
bles (laboratory tests and adverse events). Adverse events
were coded using the MedDRA dictionary. Tumor
Response Rate (complete response/partial response [CR/
PR]) was calculated considering all patients who received
at least one dose of study drug. PFS and overall survival
time were analyzed by means of Kaplan-Meier method.
Results
A total of 102 patients were enrolled in 35 Italian centers
from December 2004 to May 2005. The demographic and
baseline clinical condition of treated patients are summa-
rized in Table 1. Most of the patients were in good Per-
formance Status: 87 patients (93.6% of valuable patients)
were ECOG PS 0 to 1. Adenocarcinoma/Neoplasia NOS
was the most frequent histological type, representing
approximately half of cases.
Ninety-five of them (93.1% of enrolled) received at least
one dose of study drug. Seven patients were included but
did not receive study drug (2 because of physician deci-
sion, 2 patient decision, 2 deaths, 1 entry criteria viola-
tion).
The median received cycles was 4.0 (range 1–15), while
the median number of weeks of treatment was 12.1 (range
1.4–57.3). Fifty patients (52.6%) had dose modification
at least in one cycle: pemetrexed dose was reduced due to
adverse events in 12 patients and was delayed (mostly due
to adverse events or conflict in scheduling) in 48 patients.
The median relative dose intensity was 97.8% (range
63.1–104.0). Deviations from the scheduled dosing of
dexamethasone, folic acid and vitamin B12 were reported
in 3, 7 and 8 patients, respectively.
The main reasons for treatment discontinuation were lack
of efficacy (46 patients, 48.4%), physician decision (13,
13.7%), objective responses (13, 13.7%) and patient deci-
sion (8, 8.4%). Fifteen patients had protocol violation
and the most common was the incorrect dose reduction
due to toxicity (7 patients).
Table 1: Demographic and baseline clinical condition of the 
treated patients (n = 95)
Age, years: mean ± SD (range) 62.4 ± 10.6 (25–82)
Age ranges, N (%):
≤ 50 11 (11.6)
51–60 21 (22.1)
61–70 44 (46.3)
> 70 19 (20.0)
Sex: N (%)
Males 72 (75.8)
Females 23 (24.2)
Weight, kg: mean ± SD (range) 72.2 ± 13.6 (41–110)
NSCLC, histological type: N (%)
Neoplasia NOS, adenocarcinoma 46 (48.4)
Squamous cells 26 (27.4)
Large cells 2 (2.1)
Other 21 (22.1)
ECOG, score: N (%)
0 58 (62.4)
1 29 (31.2)
2 5 (5.4)
3 1 (1.1)
Not available 2
N = number of patients, % refers to total of treated patients with 
available dataPage 3 of 7
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Seventy-five patients (78.9% of treated) reported at least
one adverse event during the study, 34 patients (35.8%)
and 5 patients (5.2%) experienced grade 3 and grade 4
adverse events, respectively. Fifty-five patients (57.9%)
had adverse events considered by physicians as possibly
related to study treatment.
Table 2 shows adverse events reported in ≥ 5% of patients
by preferred term and study drug relationship. The most
common adverse events were pyrexia (reported in 26.3%
of treated patients and judged as drug-related in 11.6%),
asthenia (overall 13.7% of patients, drug-related in 9.5%)
and dyspnea (overall 11.6% of patients, drug-related in
only one case). General disorders and administration site
conditions (26.3%), gastrointestinal disorders (23.2%)
and blood and lymphatic system disorders (22.1%) were
the system organ classes with the highest incidence of
adverse events related to pemetrexed.
The highest incidences of CTC grade 3/4 adverse events
were reported as blood and lymphatic system disorders
(17.9%), gastrointestinal disorders (9.5%) and general
disorders and administration site conditions (9.5%).
Grade 3 adverse events reported in > 1 patient included
anemia (3 patients), leukopenia (6), neutropenia (6),
thrombocytopenia (2), diarrhea (6), nausea (2), vomiting
(2), fatigue (3), mucosal inflammation (2), thrombocyto-
penia (2), and dyspnea (3 patients). Grade 4 adverse
events included neutropenia (2 patients), and acute myo-
cardial infarction, myocardial ischemia and melaena (all
occurred in the same patient).
A total of 20 patients (21.1% of treated population) had
at least one event fulfilling the criteria for a serious adverse
event; 5 of them were considered drug-related (neutrope-
nia in 2 patients, diarrhea, pyrexia, melaena, anemia and
vomiting in 1). Overall, 19 patients (20.0%) died due to
disease progression: 5 patients (5.3%) died while on treat-
ment or within 30 days of treatment discontinuation, 14
died after 30 days from treatment discontinuation. One
patient died due to cardiac failure.
Hematological assessments were performed on 90 out the
95 treated patients. Table 3 shows the out of range hema-
tological values observed during treatment (NCIC-CTC
grading). NCIC-CTC grade 3 hematological toxicities were
the following: anemia 2.2% of patients, leucopenia
17.8%, neutropenia 18.9%, and thrombocytopenia 4.4%.
No clinically relevant changes in vital signs were reported
during the study.
Efficacy
Table 4 shows the results of the overall tumor best
response in the treated patients population with measur-
able disease at baseline (N = 87): 8 patients (9.2%; 95%:
4.1 to 17.3) were responders (1 CR and 7 PR), 23 patients
(26.4%) were stable on their disease, 49 patients (56.3%)
had disease progression as best response and 7 patients
(8.0%) were not evaluable for response.
The Kaplan-Meier survival analysis at 4.5 months
(median follow-up) was 79% (95% CI: 71 to 88%). The
median PFS was 3.1 months (95% C.I. 2.4 to 3.8).
Discussion
Previous phase 2 studies have indicated that pemetrexed
(Alimta®) has clinical activity in NSCLC. A comparative
trial of Pemetrexed and docetaxel (Eli Lilly Protocol H3E-
MC-JMEI), compared 571 patients with locally advanced
or metastatic NSCLC who had previously been treated
with chemotherapy.
Table 2: Treatment-emergent adverse events reported by ≥ 5% 
of treated patients by preferred term and study drug 
relationship: data are number of patients with rates in brackets 
(N = 95)
All Causalities Treatment Related
Patients with ≥ 1 adverse event 75 (78.9) 55 (57.9)
Pyrexia 25 (26.3) 11 (11.6)
Asthenia 13 (13.7) 9 (9.5)
Dyspnea 11 (11.6) 1 (1.1)
Neutropenia 10 (10.5) 10 (10.5)
Vomiting 10 (10.5) 9 (9.5)
Diarrhea 10 (10.5) 9 (9.5)
Anemia 10 (10.5) 8 (8.4)
Nausea 9 (9.5) 9 (9.5)
Fatigue 9 (9.5) 8 (8.4)
Cough 8 (8.4) 3 (3.2)
Anorexia 6 (6.3) 1 (1.1)
Leucopenia 5 (5.3) 5 (5.3)
Mucosal inflammation 5 (5.3) 5 (5.3)
Thrombocytopenia 5 (5.3) 5 (5.3)
Rash 5 (5.3) 4 (4.2)
Chest pain 5 (5.3) 1 (1.1)
Peripheral Edema 5 (5.3) 1 (1.1)
Table 3: Hematology abnormalities observed during treatment 
(worst NCIC-CTC grading): data are number of patients with 
rates in brackets (N = 90)
Laboratory Parameter Any grade ≥ 1 Grades 3–4
Hemoglobin 63 (70.0) 2 (2.2)
Neutrophils 50 (55.6) 17 (18.9)
Platelets 37 (41.1) 4 (4.4)
WBCs 57 (63.3) 16 (17.8)Page 4 of 7
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safety profile of pemetrexed (500 mg/m2 dose, day 1 of a
21-day cycle) as second line treatment in patients with
locally advanced or metastatic (Stage IIIB or IV) NSCLC.
Pemetrexed was supplemented with dexamethasone, folic
acid and vitamin B12 was given every 21 days. This regi-
men is recommended based on previous experiences
[17,14], which showed a significant improved tolerance
when pemetrexed is given with corticosteroids and vita-
mins supplementation.
The secondary objective of the study was to assess the
response rate in patients with measurable disease accord-
ing to the RECIST criteria.
In this study 95 patients were examined. The majority of
patients (>90%) had good clinical conditions (ECOG PS
0 or 1). The median number of cycles received was 4 and
the median number of weeks of treatment was 12.1.
Pemetrexed was well tolerated. The safety profile of peme-
trexed did not differ from what observed in previous
phase I/II studies and in the large phase III study compar-
ing pemetrexed and docetaxel as second-line treatment in
locally advanced or metastatic NSCLC [14]. In the latter
trial, which led to the regulatory approval of pemetrexed
as monotherapy for the second-line treatment of NSCLC,
the incidence of hematological toxicities (e.g. grade 3/4
neutropenia, febrile neutropenia, and neutropenia with
infections) and other drug-related adverse events was sig-
nificantly lower with pemetrexed than with docetaxel. The
results of the present study confirm the favorable toxicity
profile of pemetrexed when given over 500 mg/m2 and
supplemented by vitamin B12 and folic acid.
Vitamin supplementation significantly reduces the inci-
dence of grade 3–4 hematological toxicity, as shown in a
previous trial comparing pemetrexed administered with
or without vitamins [18].
The most frequent hematological toxicities were neutro-
penia and anemia (any grade) and the most frequent non-
hematological toxicities were pyrexia, fatigue and dyspnea
(any grade).
In the population of patients with measurable disease at
baseline the observed response rate was 9.2% and it was
similar to the Response Rate reported in the randomized
phase III study (8.8%) when pemetrexed was compared to
docetaxel [14].
It is generally agreed that response rate cannot be taken as
indicator of clinical benefit in pretreated patients with
locally advanced or metastatic NSCLC and the relation-
ship between response rate and improved survival is
unclear, so that response rate cannot be considered as a
surrogate endpoint. However, a prolonged survival in pre-
treated advanced NSCLC patients has been observed, in
spite of a response rate lower than 10%. This therefore
suggests a possible contribution from cytotoxic agents to
disease stabilization and to the clinical benefit observed
[19].
In our study, the survival at approximately 4 months
(median follow-up time) was 79% and the median pro-
gression-free survival was 3.1 months, what is in line with
the reported survival rate in the reported phase III trial by
Hanna et al. in the comparative study vs Docetaxel [14].
It is well known that, especially in 2nd line, tolerability and
toxicity profile of a cytotoxic combination might influ-
ence the choice of treatment, even when the efficacy
parameters of possible therapies (e.g. survival, progres-
sion free survival and response rate) are similar. The dura-
tion of infusion, schedule administration and patients
acceptance should be also taken into consideration for the
choice of a regimen. When compared to the other agents
currently approved for 2nd line treatment in NSCLC, the
10-minutes infusion time of pemetrexed over Day 1 of a
21-day cycle might increase the convenience of the treat-
ment and patient compliance.
Therefore, the study confirmed that pretreated patients
with locally advanced or metastatic NSCLC will likely
benefit from single-agent pemetrexed treatment (with
vitamin supplementation), with an additional advantage
in decreasing hematological (including febrile neutrope-
nia) and non-hematological toxicities.
Since, due to a minor flaw in the original study design,
there are no available data on whether patients were
treated with pemetrexed in 2nd or 3rd line, it is not possible
to assess any correlation between the number of previous
lines of treatment and response to pemetrexed.
Table 4: Results of the overall tumor response in the treated 
population: data are number of patients with rates in brackets
Best Overall Tumor Response Treated Population 
(N = 87)*
Complete Response (CR) 1 (1.1)
Partial Response PR) 7 (8.0)
Response Rate (CR + PR) 8 (9.2)
Stable Disease/No Response (SD) 23 (26.4)
Progressive Disease (PD) 49 (56.3)
Not Evaluable 7 (8.0)
*Numbers and rates refer to the amount of patients assessed for 
tumor response (response was not available in 8 patients in the 
treated population)Page 5 of 7
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Pemetrexed in combination with other agents (eg. Cispla-
tin, Carboplatin or gemcitabine) in the treatment of
advanced NSCLC may provide further clinical benefits
caused by its particular mode of action when blocking
intracellular three enzymes system. A deeper knowledge
about those enzyme system (eg: TS) may be used in future
to identify patients responders to pemetrexed [20]. The
use of targeted compounds to specific molecular path-
ways, given in addition to standard chemotherapy regi-
mens, might represent the next step in the treatment of
NSCLC and overall characteristics of pemetrexed makes it
a candidate in a tailored therapies context.
The present study contributes to provide even more infor-
mation on clinical experience with pemetrexed and fur-
ther prospective randomized clinical trials will confirm
pemetrexed (single agent or in combination) as a valid
option for pretreated locally advanced or metastatic
NSCLC patients.
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